# Missouri Attorney General Takes Legal Action Against American Shaman for Kratom Products > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/missouri-attorney-general-sues-american-shaman-kratom-products/ > **Published:** 2026-04-01T00:02:24-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:33:19-04:00 > **Clinical Summary:** Missouri attorney general sues American Shaman over kratom products, highlighting regulatory and safety concerns with CBD and kratom mixtures. --- ✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic Product SafetyKratomCbdRegulation[Legal Issues](https://cedclinic.com/ethical-legal-dilemmas-cannabis-use/) Why This Matters Legal enforcement against retailers mixing kratom with [CBD products](https://cedclinic.com/fda-warning-on-cbd-products/) highlights regulatory confusion that directly impacts patient safety and clinical decision-making. This case underscores the need for clinicians to verify product contents and understand the distinct legal and pharmacological profiles of different botanical substances. Clinical Summary Missouri’s attorney general filed suit against CBD American Shaman for allegedly selling kratom products, which are regulated differently than CBD. Kratom contains mitragynine and 7-hydroxymitragynine, opioid receptor agonists with abuse potential and [drug interaction](https://cedclinic.com/glp-1-addiction-risk-reduction-benefits/) risks, while CBD operates through different mechanisms with a distinct safety profile. The legal action reflects state-level enforcement of substance-specific regulations that vary significantly across jurisdictions. Dr. Caplan’s Take “This lawsuit illustrates why I always tell patients to demand third-party lab reports and ingredient lists—retailers mixing kratom with [CBD products](https://cedclinic.com/fda-warning-on-cbd-products/) creates both legal liability and clinical risk that patients rarely understand they’re accepting.” Clinical Perspective 🧠 Clinicians should counsel patients about the pharmacological differences between kratom and CBD, particularly regarding addiction potential and drug interactions. When patients report using products from multi-substance retailers, verification of actual contents becomes essential for safe clinical management and accurate risk assessment. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Missouri%20attorney%20general%20sues%20CBD%20American%20Shaman%20over%20kratom%20products%20-%20KY3%20%40drcaplan&url=https%3A//www.ky3.com/2026/03/31/missouri-attorney-general-sues-cbd-american-shaman-over-kratom-products/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//www.ky3.com/2026/03/31/missouri-attorney-general-sues-cbd-american-shaman-over-kratom-products/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Missouri%20attorney%20general%20sues%20CBD%20American%20Shaman%20over%20kratom%20products%20-%20KY3%20--%20via%20%40drcaplan.bsky.social%20https%3A//www.ky3.com/2026/03/31/missouri-attorney-general-sues-cbd-american-shaman-over-kratom-products/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://www.ky3.com/2026/03/31/missouri-attorney-general-sues-cbd-american-shaman-over-kratom-products/](https://www.ky3.com/2026/03/31/missouri-attorney-general-sues-cbd-american-shaman-over-kratom-products/) Table of Contents - [FAQ](#FAQ)[What is the clinical relevance rating for this cannabis news?](#What_is_the_clinical_relevance_rating_for_this_cannabis_news) - [What products are covered in this safety update?](#What_products_are_covered_in_this_safety_update) - [Why is this classified as “emerging findings”?](#Why_is_this_classified_as_8220emerging_findings8221) - [What type of regulatory issues are being addressed?](#What_type_of_regulatory_issues_are_being_addressed) - [Who should pay attention to this clinical update?](#Who_should_pay_attention_to_this_clinical_update) - [Related](#Related) ## FAQ #### What is the clinical relevance rating for this cannabis news? This article has been assigned CED Clinical Relevance #70, indicating “Notable Clinical Interest.” This rating suggests the content contains emerging findings or policy developments that healthcare professionals should monitor closely. #### What products are covered in this safety update? The article covers product safety concerns related to kratom and CBD products. These substances fall under the broader category of cannabis and related botanical products that require regulatory oversight. #### Why is this classified as “emerging findings”? The “New” designation indicates recent developments in product safety or regulatory policy. These emerging findings represent evolving information that may impact [clinical practice](https://cedclinic.com/cannabis-reproductive-health-women-clinical-evidence/) and patient safety considerations. #### What type of regulatory issues are being addressed? The article focuses on regulation and product safety concerns specific to kratom and CBD products. This likely involves updates to safety standards, quality control measures, or regulatory compliance requirements. #### Who should pay attention to this clinical update? Healthcare professionals working with cannabis and botanical products should monitor this information closely. The “Notable Clinical Interest” rating indicates relevance for clinicians involved in [patient care](https://cedclinic.com/cannabis-cardiovascular-risk-impact/) involving these substances. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Missouri attorney general sues CBD American Shaman over kratom products – KY3”, “url”: “https://www.ky3.com/2026/03/31/missouri-attorney-general-sues-cbd-american-shaman-over-kratom-products/”, “datePublished”: “2026-03-31T23:23:15Z”, “about”: “missouri attorney general sues cbd american”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Missouri attorney general sues American Shaman to stop sale of kratom, 7-OH products](https://cedclinic.com/kratom-regulatory-challenges-missouri-legal-action/) Detailed coverage of Missouri AG's legal action targeting American Shaman's kratom and 7-OH product sales, emphasizing regulatory enforcement. [Read More](https://cedclinic.com/kratom-regulatory-challenges-missouri-legal-action/) [Missouri AG sues CBD American Shaman over kratom products – KFVS12](https://cedclinic.com/missouri-attorney-general-sues-cbd-american-shaman-kratom/) News report on Missouri Attorney General's lawsuit against CBD American Shaman regarding kratom product sales and regulatory concerns. [Learn More](https://cedclinic.com/missouri-attorney-general-sues-cbd-american-shaman-kratom/) [Will hemp products be banned in 2026? Kentucky brand introduces new THC drinks](https://cedclinic.com/hemp-derived-intoxicating-products-ban-2026-kentucky-thc-drinks/) Explores upcoming hemp product regulations and market responses, relevant to understanding evolving cannabis and botanical product laws. [Explore Insights](https://cedclinic.com/hemp-derived-intoxicating-products-ban-2026-kentucky-thc-drinks/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).